Metropolis Healthcare Limited (NSE: METROPOLIS, BSE: 542650) is a Mumbai, Maharashtra-based company in the Medical Diagnostic Centres industry. With a market capitalisation of ₹11,952 Cr, it ranks #541 by market cap among the 6,197 Indian listed companies on FinBizNet, and #3 of 18 in Medical Diagnostic Centres. At ₹565.00 (as of 16 Nov 2026), the share price is 7.2% below its 52-week high of ₹609.05 and 37.1% above its 52-week low of ₹412.25. The share price is up 14.9% over one year and up 1.0% over three months.
| Current Price | ₹565.00 |
|---|---|
| Market Cap | ₹11,952 Cr |
| NSE Symbol | METROPOLIS |
| BSE Code | 542650 |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Services > Medical Diagnostic Centres |
| P/E Ratio | 61.5 |
| Return on Equity | 13.37% |
| Return on Assets | 8.36% |
| 52-Week Range | ₹412.25 – ₹609.05 |
| 1-Year Price Change | +14.9% |
| 3-Month Price Change | +1.0% |
| Beta (1Y) | 0.76 |
| Dividend Yield | 0.35% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.metropolisindia.com |
| Revenue | ₹497 Cr |
|---|---|
| Net Profit | ₹75 Cr |
| Net Margin | 15.2% |
| EPS (Basic) | ₹3.64 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Metropolis Healthcare Limited reported revenue of ₹497 Cr in Q2 FY27, up 15.8% from ₹429 Cr in Q2 FY26 and up 10.4% from ₹450 Cr in Q1 FY27. It posted a net profit of ₹75 Cr for the quarter, against a net profit of ₹53 Cr in Q2 FY26 (up 42.7%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹345 Cr (Q4 FY25) to ₹497 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹497 Cr | ₹75 Cr | 15.2% |
| Q1 FY27 | ₹450 Cr | ₹57 Cr | 12.6% |
| Q4 FY26 | ₹425 Cr | ₹51 Cr | 12.0% |
| Q3 FY26 | ₹406 Cr | ₹42 Cr | 10.4% |
| Q2 FY26 | ₹429 Cr | ₹53 Cr | 12.3% |
| Q1 FY26 | ₹386 Cr | ₹45 Cr | 11.7% |
| Q4 FY25 | ₹345 Cr | ₹29 Cr | 8.5% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 47.82% of Metropolis Healthcare Limited's shares as of Sept 2026, against 48.89% in Sept 2025 (−1.07 percentage points). Delivery averaged 53.4% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Metropolis Healthcare Limited, together with its subsidiaries, provides pathology and related healthcare services in India, Africa, South Asia, the Middle East, and internationally. The company offers routine and semi-specialised pathology tests; advanced diagnostics, including genetic, molecular, and cytogenetic testing; preventive healthcare packages and corporate wellness screening; and clinical trial research, hospital lab management, and home collection services, as well as profiles, blood tests, and soft radiology services. It also provides diagnostic services for oncology, neurology, gynecology, and nephrology, as well as various health check-up packages for men, women, senior citizens, youth, and corporates. In addition, the company develops and deals in technology driven products and services. The company serves a range of customers, including direct-to-consumer diagnostics through patient service centers, a mobile app, a website, and home collection; partnerships with standal
1. Pathology Service-This segment provides pathology and related healthcare services.
1. Pathology Service-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Dr. Lal Pathlabs Ltd | ₹33,934 Cr | 66.4 | 21.48% | ₹874 Cr | +28.7% |
| Vijaya Diagnostic Centre Limited | ₹14,665 Cr | 84.3 | 19.70% | ₹255 Cr | +38.5% |
| Metropolis Healthcare Limited | ₹11,952 Cr | 61.5 | 13.37% | ₹497 Cr | +14.9% |
| Throcare Technologies Ltd | ₹7,764 Cr | 47.6 | 28.74% | ₹271 Cr | +7.5% |
| SURAKSHA DIAGNOSTIC LIMITED | ₹1,856 Cr | 55.4 | 13.84% | ₹99 Cr | +6.9% |
| Krsnaa Diagnostics Ltd | ₹1,625 Cr | 16.8 | 10.89% | ₹271 Cr | -27.0% |
| Gaudium IVF and Women Health Limited | ₹803 Cr | 27.4 | 16.08% | ₹37 Cr | — |
| Chandan Healthcare Limited | ₹582 Cr | 21.9 | 18.43% | ₹81 Cr | — |
| Aspira Pathlab & Diagnostics Ltd | ₹127 Cr | 2,360 | — | — | +115.2% |
Listed by market capitalisation. Ratios are shown for context only.
Metropolis Healthcare Limited is trading at ₹565.00, with a market capitalisation of ₹11,952 Cr.
Metropolis Healthcare Limited operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Services > Medical Diagnostic Centres).
Metropolis Healthcare Limited has a P/E of 61.5 and a return on equity of 13.37%.
Metropolis Healthcare Limited is listed on the NSE under the symbol METROPOLIS and on the BSE under the scrip code 542650.
Metropolis Healthcare Limited's share price is up 14.9% over one year and up 1.0% over three months. Its 52-week range is ₹412.25 to ₹609.05.
In Q2 FY27, Metropolis Healthcare Limited reported revenue of ₹497 Cr and net profit of ₹75 Cr, with basic EPS of ₹3.64 (consolidated, parsed from the company's exchange filing).
Metropolis Healthcare Limited reported revenue of ₹497 Cr in Q2 FY27, up 15.8% from ₹429 Cr in Q2 FY26 and up 10.4% from ₹450 Cr in Q1 FY27.
Promoters held 47.82% of Metropolis Healthcare Limited's shares as of Sept 2026, against 48.89% in Sept 2025 (−1.07 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.